

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Neuralab Limited	06/19/2006
RECEIVING PARTY DATA	
Name:	Elan Pharma International Limited
Street Address:	Monksland
City:	Athlone, County Westmeath
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6787523
CORRESPONDENCE DATA	
Fax Number:	(650)625-8110
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650-625-8100
Email:	rcelli@sughrue.com
Correspondent Name:	Rosemarie L. Celli
Address Line 1:	Sughrue Mion PLLC
Address Line 2:	401 Castro Street, Suite 220
Address Line 4:	Mountain View, CALIFORNIA 94041
ATTORNEY DOCKET NUMBER:	CA1278
NAME OF SUBMITTER:	Rosemarie L. Celli
Total Attachments: 2	
source=US Patent No 6787523 Executed Assignment from Neuralab to EPIL#page1.tif	
source=US Patent No 6787523 Executed Assignment from Neuralab to EPIL#page2.tif	

CH \$40.00 6787523

209-US-CIP4

## ASSIGNMENT

THIS ASSIGNMENT, by NEURALAB LIMITED, a company incorporated under the laws of BERMUDA and having its principal place of business 102 ST. JAMES COURT, FLATTS, SMITH FL04, BERMUDA (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, by virtue of an Assignment [recorded in the United States Patent and Trademark Office, at reel 010794, frame 0764], the Assignor is the owner of the entire right, title and interest of the invention set forth as follows:

Title of Invention: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Filing Date: November 30, 1998

Application No.: 09/201,430 issued as U.S. Patent No. 6,787,523

WHEREAS, ELAN PHARMA INTERNATIONAL LIMITED, a private limited company incorporated under the laws of Ireland, and having its registered office at WIL HOUSE, SHANNON BUSINESS PARK, SHANNON, COUNTY CLARE, IRELAND (hereinafter referred to as "the Assignee"), pursuant to a Deed of Agreement dated as of November 26, 2005 (hereinafter referred to as "the EPIL Agreement"), between Assignor and Assignee, has acquired the Assignor's right, title, and interest in and to said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the EPIL Agreement, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the above-mentioned invention, the right to file applications on said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, Assignor has signed its name on the date indicated.


NEURALAB LIMITED

Date: JUNE 19, 2006



By: 

Name: Kevin Insley

Title: President and Chief Financial Officer

  
\_\_\_\_\_  
David J. Boyle J/P.

Notary Public and Commissioner for Oaths  
Conyers Dill & Pearman  
Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda  
441-295-1422



39724-1